Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Imatinib in Metastatic Androgen-Independent Prostate Cancer
NCT00080678Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2003
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Docetaxel + Imatinib Mesylate with Docetaxel + Placebo (2 arms). Primary endpoint: Time to progression at 3 years. Started May 2003; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00080678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080678.